BioSpace News Archive

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) today announced that a second patient has been successfully treated with TFF Pharmaceuticals’ proprietary Voriconazole Inhalation Powder (“TFF VORI”) through a compassionate use program.

Jazz Pharmaceuticals plc announced that the company will participate in the following upcoming investor conferences.

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release third quarter 2022 financial results after market close on Tuesday, November 8, 2022.

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2022 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones.

McKesson Corporation (NYSE: MCK) has released its fiscal 2023 second-quarter financial results.

Exelixis, Inc. and Sairopa B.V. announced that the companies have entered into an exclusive clinical development and option agreement for ADU-1805, a potentially best-in-class monoclonal antibody that targets SIRPα.

Pipeline Therapeutics announced that management will present at the following investor conferences during November 2022.

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report third quarter financial results on Wednesday, November 9, 2022.

Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK) today announced it will report third quarter 2022 financial results and provide a general business overview on Tuesday, November 8, 2022.

Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, announced the appointment of Richard Rodgers, MBA to its board as an independent director.